CSPC Pharmaceutical Group (HK:1093) has released an update.
CSPC Pharmaceutical Group Limited has announced that its new drug, Omalizumab for Injection (branded as Enyitan®), has received marketing approval from the National Medical Products Administration (NMPA) of China. Enyitan® represents the first biosimilar of Xolair® in China, intended for patients over 12 years old with chronic spontaneous urticaria unresponsive to H1 antihistamine treatments. This approval marks a significant expansion of CSPC’s product line in the autoimmune disease category.
For further insights into HK:1093 stock, check out TipRanks’ Stock Analysis page.
